Stryker 完成对 ZuriMED 的收购,将 FiberLocker 肩袖修复器械纳入产品线
Stryker completes ZuriMED takeover
Stryker 已完成对瑞士 ZuriMED 的收购,将肩袖修复器械 FiberLocker System 纳入其运动医学与肩部护理产品线。该器械由聚酯短纤维不可降解植入物与手术微型缝合固定装置组成,2024 年获 510(k) 许可,申报依据为台架与动物性能试验。ZuriMED 已于 2025 年启动瑞士首次人体安全性研究及美国多中心试验,后者主要终点为治疗后 6 个月愈合评估。
An article from
Dive Brief
The deal expands Stryker’s portfolio of fast-growing sports medicine and shoulder care devices.
Published Oct. 27, 2026
By
This audio is auto-generated. Please let us know if you have feedback.
Dive Brief:
- Stryker said Monday it has closed its takeover of ZuriMED, adding a device for treating rotator cuff tears to its portfolio.
- ZuriMED sells the FiberLocker System, a 510(k)-cleared medical device for reinforcing the rotator cuff after or during shoulder repair.
- Stryker bought the device to expand its offering to specialists across sports medicine and shoulder care.
Dive Insight:
FiberLocker has two components. One component is a non-degradable implant made of polyester staple fibers. The other is a surgical micro-stapling device for fixing the implant in soft tissue. Fixing the medical felt patches in place reinforces the rotator cuff after or during repair. Sutures or bone anchors provide mechanical strength for the repair.
ZuriMED received 510(k) clearance in 2024. The Switzerland-based company based its 510(k) filing on bench and animal performance tests.
Investigators started testing the device in humans in 2025. That year, ZuriMED began a first-in-human study at a site in Switzerland and initiated a multicenter trial in the U.S. The Swiss trial is focused on safety. The primary endpoint of the U.S. study is assessing healing six months after treatment.
The rotator cuff retear rate after three to six months is 21%, according to a systematic review and meta-analysis published in 2021. ZuriMED is using magnetic resonance imaging to assess the effect of FiberLocker on healing.
FiberLocker will further expand Stryker’s portfolio of shoulder implants. In July, Stryker CFO Preston Wells named the company’s expanded range of shoulder implant products as a driver of double-digit sports medicine growth in the second quarter. Wells highlighted the full commercial launch of Mako Shoulder on the Mako 4 robot as another driver of growth in the shoulder business.
Stryker's M&A activity has focused on the peripheral vascular business over the past two years. In February 2025, the company closed its takeover of Inari Medical, adding venous thromboembolism clot removal technologies to its portfolio. Stryker completed the acquisition of Amplitude Vascular Systems in May to add an intravascular lithotripsy platform to its peripheral vascular portfolio.
来源:MedTech Dive 器械媒体 · medtechdive.com